Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804
Q4 FY19 results · Jan–Mar 2019
Aurobindo Pharma reported revenue from operations of ₹5,292.20 crore and net profit of ₹585.22 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 5,292.20 | — | — | 5,269.67 | +0.4% |
| Other income | 32.27 | — | — | 63.85 | −49.5% |
| Total income | 5,324.47 | — | — | 5,333.52 | −0.2% |
| Profit before share of associates & JVs and tax | 816.86 | — | — | 914.42 | −10.7% |
| Share of profit/(loss) of associates & JVs | (0.52) | — | 2.57 | ||
| Net profit for the period | 585.22 | — | — | 712.21 | −17.8% |
| Attributable to shareholders of the company | 585.38 | — | — | 538.77 | +8.7% |
| EPS, basic (₹) | 9.99 | — | — | 12.15 | −17.8% |
| Net margin (%) | 11.1 | — | 13.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,280.58 | — | — | 3,248.10 | +1.0% |
| Other income | 28.31 | — | — | 136.87 | −79.3% |
| Total income | 3,308.89 | — | — | 3,384.97 | −2.2% |
| Profit before tax | 618.48 | — | — | 584.68 | +5.8% |
| Net profit for the period | 460.14 | — | — | 463.51 | −0.7% |
| EPS, basic (₹) | 7.85 | — | — | 7.91 | −0.8% |
| Net margin (%) | 14.0 | — | 14.3 |
Consolidated
- Filed with BSE
- 29 May 2019, 12:59 IST
- Board meeting
- 28 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 May 2019, 12:59 IST
- Board meeting
- 28 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE